文献速递口腔修复与种植

特立帕肽局部递送促进接受自助餐饮食和双膦酸盐的去卵巢大鼠的骨整合

Teriparatide Topical Delivery Supports Osseointegration in Ovariectomized Rats Receiving Cafeteria Diet and Bisphosphonate: An In Vivo Experimental Study.
PubMed 文献 · Clin Oral Implants Res · 2026-10-26

本研究探讨特立帕肽涂层钛种植体在雌激素缺乏、自助餐饮食及利塞膦酸治疗的大鼠模型中是否增强骨整合。体外实验显示10和40 ng特立帕肽均促进矿化结节形成,故选10 ng用于体内。48只大鼠分三组植入涂层或未涂层种植体,28天后评估显示特立帕肽显著提高拆除扭矩和种植体周围骨量,并上调成骨和血管生成标志物。

要点

  • 特立帕肽涂层可显著提高所有组别的拆除扭矩,OVX/CD/RIS组增幅最大。
  • 特立帕肽增加OVX/CD和OVX/CD/RIS组的种植体周围骨量。
  • 局部特立帕肽递送改善雌激素缺乏、自助餐饮食及双膦酸盐治疗下的种植体周围骨修复。

核心结论

  • 局部特立帕肽递送可改善雌激素缺乏、自助餐饮食及双膦酸盐治疗条件下的种植体周围骨修复。

研究设计与样本

  • 体外实验评估10或40 ng特立帕肽涂层钛片的生物反应并用UV-Vis光谱确认药物吸附。
  • 体内实验将48只大鼠随机分为SHAM、OVX/CD和OVX/CD/RIS三组,双侧上颌植入涂层或未涂层钛种植体,28天后处死评估。

主要发现

  • 体外实验中10和40 ng特立帕肽均成功促进矿化结节形成。
  • 体内实验中特立帕肽显著提高所有组别的拆除扭矩,OVX/CD/RIS组增幅最大。
  • 特立帕肽增加OVX/CD和OVX/CD/RIS组的种植体周围骨量,经micro CT和荧光显微镜确认。
  • RT-qPCR证实特立帕肽上调成骨和血管生成标志物。

临床怎么用

  • 对于存在雌激素缺乏、自助餐饮食及双膦酸盐治疗背景的种植患者,特立帕肽涂层种植体可能改善骨整合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postmenopausal osteoporosis associated with cafeteria diet and bisphosphonate therapy may impair peri-implant bone repair. Therefore, strategies to enhance osseointegration are needed. AIM: This study investigated whether teriparatide-coated implant surfaces enhance osseointegration in a rodent model of estrogen deficiency (OVX) and cafeteria diet (CD) treated with risedronate (RIS). MATERIAL AND METHODS: In the in vitro phase, titanium discs coated with 10 or 40 ng of teriparatide were evaluated by in vitro bioassays, and drug adsorption was confirmed by UV-Vis spectroscopy. As both loading amounts produced similar biological responses, 10 ng was selected for the in vivo phase. In the in vivo phase, 48 rats were randomly assigned to SHAM (sham-operated control), OVX/CD (ovariectomized with cafeteria diet), or OVX/CD/RIS (ovariectomized with cafeteria diet and risedronate) groups. Titanium implants either coated with teriparatide using a layer-by-layer topical drug delivery system or left non-coated were placed bilaterally in the maxilla. Rats were euthanized after 28 days. Osseointegration was evaluated by removal torque testing, micro computed tomography, fluorescence microscopy, and RT-qPCR analysis. RESULTS: In the cell culture experiment, both teriparatide amounts successfully promoted mineralized nodule formation in vitro and UV-Vis spectroscopy confirmed drug adsorption. In vivo, teriparatide significantly increased removal torque across all groups, with the greatest increase in OVX/CD/RIS. Teriparatide also increased peri-implant bone volume in OVX/CD and OVX/CD/RIS, confirmed by micro computed tomography and fluorescence microscopy. RT-qPCR also confirmed upregulation of osteogenic and angiogenic markers. CONCLUSION: Topical teriparatide delivery improves peri-implant bone repair under estrogen deficiency, cafeteria diet, and bisphosphonate therapy.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. da Silva ACE, Batista FRS, Hassumi JS, et al. Teriparatide Topical Delivery Supports Osseointegration in Ovariectomized Rats Receiving Cafeteria Diet and Bisphosphonate: An In Vivo Experimental Study. Clin Oral Implants Res. 2026. PMID: 42931806. doi:10.1111/clr.70187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。